Blood-brain barrier leakage is associated with cognitive decline and brain abnormalities during aging.
ID
Bron
Verkorte titel
Aandoening
Cognitive aging/ cognitieve veroudering
Blood-brain barrier leakage/ bloed-hersenbarrière lekkage
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
• Episodic memory<br>
• Hippocampal volume<br>
• Blood-brain barrier leakage
Achtergrond van het onderzoek
The brain is vulnerable to age-related pathologies, which can result in cognitive decline. Nevertheless, some people age successfully, while others suffer substantially from this cognitive decline. To date, the exact mechanism of cognitive aging remains unclear. A potential initiating mechanism is Blood-Brain Barrier (BBB) breakdown. BBB breakdown can cause a suboptimal environment for neuronal cells and results in several pathological changes, which may eventually lead to neuronal damage and cognitive decline. Most techniques to detect BBB breakdown are not sensitive enough to detect the subtle leakage that characterizes normal aging, so that previous BBB studies did not focus on normal cognitive aging. A promising method to detect subtle BBB leakage in vivo in humans is Dynamic Contrast-Enhanced (DCE) Magnetic Resonance Imaging (MRI). Recently, we developed a new DCE MRI scan sequence, making our DCE MRI scan sensitive enough to detect subtle globally distributed leakage spots. We will use this innovative DCE MRI scan in a successfully aging sample. We have been allowed access to the MAastricht Aging Study (MAAS) database to collect our sample, which provides the unique opportunity of having a sample with cognitive pre-measurements already conducted from 1993 to 2005. We will use this information to investigate the association between BBB leakage and cognitive decline over the past 23 years and the association between BBB leakage and radiologically visible brain tissue abnormalities.
Doel van het onderzoek
Blood-brain barrier leakage is associated with cognitive decline and brain abnormalities during aging.
Onderzoeksopzet
Two sessions with one week between sessions
Onderzoeksproduct en/of interventie
Participants will be subjected to blood sampling, neuropsychological assessment (approximately 60 minutes with five cognitive tests) and MRI scanning (approximately 60 minutes).
Publiek
Inge Verheggen
P.O. Box 616
Maastricht 6200 MD
The Netherlands
+31 (0)43-3884088
inge.verheggen@maastrichtuniversity.nl
Wetenschappelijk
Inge Verheggen
P.O. Box 616
Maastricht 6200 MD
The Netherlands
+31 (0)43-3884088
inge.verheggen@maastrichtuniversity.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
• Informed consent before participation
• Participation in 12-year follow-up of MAAS
• MMSE score ≥ 25
• DAD score > 90%
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
• Contraindications for scanning (e.g. brain surgery; cardiac pacemaker; metal implants; claustrophobia; large body tattoos)
• Contraindications for the gadolinium-containing contrast agent (renal failure) as determined by the eGFR < 30 mL/min
• Diagnosis of dementia, prodromal dementia or MCI (in case of doubt, prof. dr. Frans R.J. Verhey will determine whether the participant may be included)
• Diagnosis of other psychiatric or neurological disorders (major depression (< 12 months); history of schizophrenia; bipolar disorder; psychotic disorder NOS or treatment for a psychotic disorder (< 12 months); cognitive impairment due to alcohol abuse; epilepsy; Parkinson's Disease; Multiple Sclerosis; brain surgery; brain trauma; past electroshock therapy; kidney dialysis; Menière's Disease; brain infections)
• Structural brain abnormalities, as is thus far known from the medical history or will later become evident on the scan.
• Cognitive impairment due to alcohol/drug abuse or abuse of other substances
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL6358 |
NTR-old | NTR6542 |
CCMO | NL54944.068.16 |
OMON | NL-OMON47086 |